Moderna
Preço: 49.91Empresa e modelo de negócios
Moderna is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. Its core products include the COVID-19 vaccine and various candidates for infectious diseases, cancer, and rare diseases. The company primarily generates revenue from vaccine sales, with a significant portion derived from government contracts and partnerships. Moderna's business segments include research and development, manufacturing, and commercialization of its mRNA-based products.
Perfil de investimento
The investment profile of Moderna is more aligned with growth investors, given its focus on innovative mRNA technology and potential future product pipeline. However, the high risk associated with its current financial performance and market volatility may deter conservative investors. The stock may appeal to those with a medium to long-term horizon who are willing to navigate potential fluctuations.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -8.15 Risco
- Receita QoQ — crescimento da receita trimestre contra trimestre
- -42.6% ↓
- Surpresa de EPS
- 60.9% melhor que o esperado
- Volatilidade 20d
- 3.9% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-11 05:23 | Manter | Vender | scenario_deterioration |
| 2026-06-05 02:43 | Vender | Manter | Weak fundamentals offset by recent price momentum. |
| 2026-06-03 02:47 | Manter | Vender | scenario_deterioration |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-05-04 13:36 | UBS | Preço-alvo elevado | 36 → 45 | 47.465 |
| 2026-05-04 12:36 | RBC Capital | Preço-alvo elevado | 35 → 38 | 46.87 |
| 2026-05-01 23:40 | Goldman Sachs | Preço-alvo elevado | 43 → 49 | 45.37 |
Nada ainda